Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extranodal non-Hodgkin lymphoma. The predominant subtype is diffuse large B-cell lymphoma (DLBCL), and no systematic lesion is identified at diagnosis. BTKi (Bruton’s tyrosine kinase inhibitor) has demonstrated significant clin...
Main Authors: | Ying Liu, Jie Sun, Kangxin Tuo |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2023-04-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/529315 |
Similar Items
-
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
by: Alsuhebany N, et al.
Published: (2023-11-01) -
Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases
by: Liang Wang, et al.
Published: (2021-04-01) -
Zanubrutinib-induced aseptic meningitis: a case report and literature review
by: Jinjun Yang, et al.
Published: (2023-08-01) -
Case Report: Intraocular Hemorrhage in a Primary Vitreoretinal Lymphoma Patient Treated With Zanubrutinib
by: Xiao Zhang, et al.
Published: (2022-03-01) -
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
by: Javier Muñoz, et al.
Published: (2022-10-01)